The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Great. Thank you so much, Diana, for that wonderful presentation. (Conference Instructions)
I have a couple, Diana. One of them is a bigger picture question on the NASH space and monotherapy versus combo therapy. Can you just give us
a sense -- obviously, you're doing 501 and 101 monotherapy, but the ultimate goal of going into combo therapy. There are a lot of competitive or
competitor NASH programs in this space. Just curious what's the relative percentage that are pursuing monotherapy versus combo therapy roughly.
And do you see -- we've been talking about combo therapy for couple of years now in the NASH space. Do you see that, ultimately, this is where
it's going, just given some of the later-stage results in NASH to date?
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Yeah. And so you have the FXR agonist and the THR-beta agonist. Is the thinking that you sort of need to have the approach of your FXR is dealing
with the anti-fibrotic aspect and maybe the THR-beta is sort of dyslipidemia, perhaps, to classify these things? But you also have 601 with the GLP-1
that's more metabolic. Just curious, do you really see the mixing and matching up of the different modalities here as you really need that core FXR
agonist as the anti-fibrotic piece? Or could you see other combos where you don't have that FXR agonist?
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Yeah. And I guess final question on the GLP-1 agonist. You mentioned in your presentation that you could potentially develop it for NASH as well
as obesity. Was it just a matter of timing in terms of thinking about whether or not to include that in a NASH combo trial? Or do you still have the
flexibility to potentially pop that in with your FXR agonist or something like that? You just have to see how the data plays out, I suppose?
Question: Joey Stringer - Needham & Company, LLC - Analyst
: Great. Well, we're out of time for this session. Thank you so much, Diana, for the presentation and fielding the Q&A. Thanks to everyone else for
joining us on the webcast. Everyone, have a good day.
|
